

Cell and Gene Therapy Catapult

UK 2023 ATMP Clinical Trials Database

This clinical trial database covers all ATMP trials taking place in the the UK in 2023.

Ongoing trial numbers in the UK have stayed steady (175 in 2023 vs 178 in 2022), while global trials have dropped by 10%.

Here, we highlight key data from the database

UK strength: Clinical trial capability

There has been a steady state in the number of ongoing clinical trials in the UK. This is in contrast to a ~10% decrease in global trials.






UK remains an attractive location for commercially sponsored ATMP trials




Academic/non-profit and commercial ATMP clinical trials.



Data from ARM 2023 CT report and CGT Catapult 2023 ATMP Clinical Trials Database


Ongoing ATMP trials in the UK by clinical phase 2018-2023

The pipeline remains strong with good early phase numbers and continued progression to later phases.




The majority of trials involve genetically modified therapies

Most ATMP trials in 2023 were gene therapies (76%), with an even distribution between *in vivo* and *ex vivo* gene therapy trials.




Distribution of UK ATMP clinical trials by therapeutic area

Oncology remains the dominant therapeutic area under investigation, followed by a good diversity of other therapeutic areas.







View the full 2023 ATMP Clinical Trials Database on the Cell and Gene Therapy Catapult website:

https://ct.catapult.org.uk/resources/clinical-trials-database